Brepocitinib - CISMeF

Preferred Label : Brepocitinib;

NCIt synonyms : TYK2/JAK1 Inhibitor PF-06700841;

NCIt definition : An orally available, selective inhibitor of non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2) and tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1) with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, brepocitinib selectively binds to and inhibits the activation of TYK2 and JAK1, thereby disrupting TYK2 and JAK-1-dependent cytokine signaling. This may reduce inflammatory responses and prevent inflammation-induced damage caused by certain immunological diseases. TYK2 and JAK-1 are members of the Janus kinase family of non-receptor tyrosine kinases and are involved in signaling pathways affecting hematopoiesis, immunity and inflammation.;

UNII : 3X8387Q25N;

InChIKey : BUWBRTXGQRBBHG-MJBXVCDLSA-N;

CAS number : 1883299-62-4;

Molecule name : PF-06700841; PF 06700841; PF-841;

NCI Metathesaurus CUI : CL970417;

Details

Origin ID

C161798;

UMLS CUI

C5206103;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
has_target
- Non-Receptor Tyrosine-Protein Kinase TYK2 [NCIt concept]
- Tyrosine-Protein Kinase JAK1 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients